MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9819
+0.0994
+11.26%
After Hours: 0.9700 -0.0119 -1.21% 19:48 07/15 EDT
OPEN
0.8700
PREV CLOSE
0.8825
HIGH
1.000
LOW
0.8700
VOLUME
2.88M
TURNOVER
--
52 WEEK HIGH
2.720
52 WEEK LOW
0.2110
MARKET CAP
58.55M
P/E (TTM)
-0.6302
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DFFN stock price target is 3.500 with a high estimate of 3.500 and a low estimate of 3.500.

EPS

DFFN News

More
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers Party City Holdco Inc. (NYSE: PRTY) rose 34.4% to $1.74 in pre-market trading after the company announced it regained compliance with NYSE continued listing standards.
Benzinga · 07/08 11:16
Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC
GlobeNewswire · 07/07 13:00
Diffusion Pharma files IND to launch COVID-19 program with trans sodium crocetinate
Seeking Alpha - Article · 07/07 12:39
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential
TipRanks · 07/07 00:47
ENPH, WLL among premarket gainers
Seeking Alpha - Article · 06/18 12:17
Diffusion Pharma 8-K Showed Shareholder Proposal For Stock Split Did Not Receive Requisite Number Of Votes To Be Approved
Benzinga · 06/17 20:52
CORRECTION: Diffusion Pharma 8-K Showed Proposal No. 3 Did Not Receive The Requisite Number Of Votes For Approval At The Annual Meeting
Benzinga · 06/17 20:51
Diffusion Pharma to initiate early-stage TSC study in COVID-19 patients in Europe
Seeking Alpha - Article · 06/11 13:52

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About DFFN

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
More

Webull offers kinds of Diffusion Pharmaceuticals Inc stock information, including NASDAQ:DFFN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFFN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DFFN stock methods without spending real money on the virtual paper trading platform.